SEB Equities upgraded Zealand Pharma (ZLDPF) to Buy from Hold with an DKK 850 price target Light Up your Portfolio with Spark:Easily identify ...

Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker ...

Viking Therapeutics (VKTX) stock gains as Roche (RHHBY) and Zealand Pharma's (ZLDPF) $5.3B deal for obesity drugs lifts ...

Zealand Pharma (ZLDPF) and Roche (RHHBY) entered a collaboration and license agreement to co-develop and co-commercialize petrelintide as a ...

Roche (RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Zealand Pharma AS (ZLDPF) reported significant clinical advancements in their obesity pipeline, particularly with petrelintide and survodutide. The company has a strong cash position of DKK9 ...

Stay updated on market trends for ZLDPF. Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names The $200B GLP-1 market ...

Check a company’s competitiveness in the job market with alternative data that tracks hiring, job openings, and more.

Zealand Pharma AS (ZLDPF) reported significant clinical advancements in their obesity pipeline, particularly with petrelintide and survodutide. The company has a strong cash position of DKK9 billion, ...